SOUTH SAN FRANCISCO, Calif., Feb. 4, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) a clinical stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that CEO Peter J. Langecker, M.D., Ph.D., will present a corporate overview and update at the BIO CEO and Investor Conference on Monday, February 14th, at 1:30 p.m. EST (10:30 a.m. PST), in the Waldorf-Astoria Hotel's Conrad Suite in New York City, NY. An archived webcast of the presentation can be accessed for 30 days following the presentation under the Investor Center tab at www.oxigene.com .
About OXiGENE, Inc.
OXiGENE is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients.The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969
CONTACT: Investor and Media Contact: Michelle Edwards, Investor Relations firstname.lastname@example.org 650-635-7006